Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...
Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons,” published in the November 2024 issue of Infectious ...
In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of H ...
Interesting Engineering on MSN23h
From chronic to curable: Twice-yearly shot shows near-total HIV eradicationScientists have developed Lenacapavir, a twice-yearly injection that cuts HIV infection risk by 96% in groundbreaking trials.
India Today on MSN6h
New injection reduces risk of HIV infection by 96%: All about itA new HIV prevention method, Lenacapavir, administered as a twice-yearly injection, has demonstrated superior results ...
Lenacapavir will be available at low cost in 120 poor countries. But nearly all of Latin America was excluded from a deal ...
Sunlenca's biannual shot could revolutionize HIV prevention, but access remains a key barrier, particularly in Latin America.
World AIDS Day is observed on December 1 annually. The theme this year is ‘Take the Rights Path: My Health, My Right’. It is ...
Tengrinews.kz - A revolutionary HIV drug has been created: clinical trials have shown that its twice-yearly injections are 96 ...
The results showed the high prevention effectiveness of the six-monthly long-acting injectable drug lenacapavir for cisgender adolescent girls and women, cisgender men, and transgender women. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback